News About: Pharm. Affairs
Companies including Daewon and Ahngook challeges to ezetimibe complex market
Korean companies are developing fierce competition in the market of complexes having the more powerful function to inhibit cholesterol than the combination of statin and ezetimibe.
They all are planning to launch th...
Alvogen & AZ signs sales agreement of 3 antibodies for breast and prostate cancer
On the 11th, Alvogen Korea(CEO Young-Hee Jang) announced the Korean exclusive sales agreement of AstraZeneca’s(CEO Liz Chatwin) antibodies, Zoladex(generic name: goserelin), Arimidex(generic name: anastrozole) and Cas...
Multinational logistics companies aiming for Korean pharma market
The domestic pharmaceutical distribution market has been threatened by multinational logistics companies.
Cardinal Health started to have a business in Korea as signing a distribution agreement with Severance Hospita...
Boehringer returns license of EGFR targeted therapy Olmutinib to Hanmi
Over the previous official announcement of the ‘Partnership Agreement before Technology Introduction’ containing terms and conditions that Boehringer Ingelheim has the exclusive right for every indication of ‘HM61713’...
About 40 generic companies enters ‘Twynsta’ market
Generics of ‘Twynsta(telmisartan, amlodipine),’ a leading drug in the hypertension complex market, are getting ready to be released.
As Twynsta lost the exclusivity with the expiration of the PMS(post-marketing surve...
Champix generics’ attempt to launch early, challenged by 14 companies
After challenges have been made to the substance patent of the Pfizer’s antismoking treatment Champix, other 14 Korean companies participated in the attempt. Once they get successful in the challenge, Champix generics...
3-way competition among Boehringer, Astra & MSD over new antidiabetic complexes
In the Korean diabetes treatment market, a 3-way competition is expected among complexes in combination with DPP-4 and SGLT-2 inhibitors.
According to MSD, ‘ertugliflozin,’ a SGLT-2 inhibitor jointly being developed ...
Toujeo & Jardiance landed in Samsung Medical Center
22 new pharmaceutical products, such as Sanofi-Aventis’ next-generation basal insulin Toujeo and Boehringer Ingelheim’s Jardiance, succeeded in newly landing in Samsung Medical Center.
According to the industry con...
Rapidly enlarging dementia treatment market, attracting domestic companies too
Encountering the rapid aging society, overcoming dementia for elders has become a huge social issue. An increasing number of dementia patients enlarges its market; thus, the Alzheimer’s disease market accounting for 5...
Samsung applies for approval of Humira biosimilar
Samsung is about to secure a pipeline with biosimilars of the top 3 ‘TNF-alpha inhibitors.’
After a ‘Enbrel(etanercept)’ similar, ‘Lenflexis,’ and a ‘Remicade(infliximab)’ similar, ‘Brenzys,’ the company filed for a...
